ArticleHead & face medicine2026
SLC15A4 promotes oral cancer progression by regulating TLR9 and activating the JAK/STAT signaling pathway.
Article in Head & face medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOral cancer continues to pose a major health problem worldwide, characterized by few treatment options and an unfavorable prognosis. The solute carrier family 15 member 4 (SLC15A4) has been reported to be associated with immune responses regulation and tumor progression. This study purpose was to reveal the role of SLC15A4 in regulating Toll-like receptor 9 (TLR9) activation and the subsequent JAK/STAT signaling pathway in the context of oral cancer progression.
methodsClinical samples from 38 oral cancer patients were analyzed for SLC15A4 and TLR9 expression using qPCR, Western blot, and immunohistochemistry (IHC). In vivo validation was performed using a xenograft mouse model. CAL27 and FaDu cell lines were used to study the effects of SLC15A4 knockdown on cell proliferation, migration, invasion, and inflammatory response via CCK8, ELISA, and transwell assays. SLC15A knockout and TLR9 overexpression were detected to explore their relationship with JAK/STAT signaling by detecting subcellular localization, JAK/STAT1 activation, cell invasion, migration, proliferation and inflammatory responses. The JAK/STAT agonist RO8191 was used to assess the impact of pathway activation on cell behavior.
resultsSLC15A4 was overexpressed in both tissue and cell line of oral cancer. Knockdown of SLC15A4 significantly reduced cell proliferation, migration, invasion, and inflammatory cytokine secretion (IL-6, IL-1β, TNF-α). Both STAT1 and STAT3 phosphorylation were suppressed, and JAK/STAT pathway activation restored these phenotypes. SLC15A4 knockdown also decreased TLR9 expression in cells. TLR9 overexpression restored the effects of SLC15A4 knockdown. TLR9 was shown to activate the JAK/STAT signaling pathway in oral cancer cells. Finally, activation of the JAK/STAT pathway reversed the effects of SLC15A4 knockdown.
conclusionSLC15A4 is essential in promoting oral cancer progression by regulating TLR9 activation and subsequent JAK/STAT signaling. This regulatory pathway influences cell proliferation, migration, invasion, and inflammation, highlighting SLC15A4 as a potential therapeutic target in treatment of oral cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.